Quest Diagnostics (DGX) Director Robert B. Carter Buys 11 Shares

What Happened

• Robert B. Carter, a director of Quest Diagnostics (DGX), acquired 11 shares of company stock on July 22, 2026.
• The shares were acquired at $206.80 each for a total of about $2,275. This was a small purchase via a dividend reinvestment plan, not an open-market trade.

Key Details

• Transaction date and price: 2026-07-22 — 11 shares at $206.80 ($2,274.80, reported as $2,275).
• Filing date: Form 4 filed 2026-07-27 (Accession 0001022079-26-000085).
• Shares owned after transaction: not disclosed in this filing.
• Footnote: The shares were acquired under a dividend reinvestment plan administered by the reporting person's broker and are eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report this transaction early on Form 4.
• Timeliness: The filing notes the dividend reinvestment treatment (eligible for deferred reporting); the filer elected to report it on Form 4 rather than defer.

Context

• Dividend reinvestment purchases are routine and typically small; they reflect automatic reinvestment of dividends rather than an active market buy.
• Purchases by directors can be interpreted as mildly positive but this single, small transaction ($~2.3k) is unlikely by itself to signal a material change in insider conviction.